Navigation Links
MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Date:8/19/2007

- Company Further Expands Anti-Interleukin-9 Program with Second Phase 2a

Study -

GAITHERSBURG, Md., Aug. 1 /PRNewswire/ -- MedImmune, Inc. today announced that it has initiated a multi-dose, Phase 2a clinical trial with its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma. The placebo-controlled, dose-escalation study is designed to evaluate the safety and tolerability of multiple doses of the antibody. This trial is the second Phase 2a study currently underway with the MAb, known as MEDI-528.

"We are excited to advance the investigation of this potential treatment for patients with asthma and to further explore the role of IL-9 in the pathology of this disease," said Barbara White, M.D., vice president, clinical development, inflammatory disease. "Recent preclinical study results have provided new insight about IL-9's role in a host of functions associated with the onset of asthma, including allergic inflammation in the airways and allergen-induced airway modeling. These data further support our hypothesis that an antibody blocking IL-9 may represent a new long-term maintenance or controller therapy for symptomatic, persistent asthma."

Two Phase 1 single-dose, dose-escalation studies have been conducted to evaluate the safety, tolerability and pharmacokinetics of the anti-IL-9 MAb in healthy volunteers. The antibody was well tolerated in both studies. The company is also conducting an ongoing Phase 2a study, initiated in late 2006, to evaluate the efficacy of a single intravenous dose of MEDI-528 and its effect on disease mechanisms in adults with atopic asthma. MedImmune plans to initiate a third Phase 2a study to evaluate the ability of MEDI-528 to inhibit the biological activity of IL-9 in the bronchoalveolar lavage fluid of adult patients with atopic asthma.

About IL-9

As mentioned above, IL-9 has been associated with symptoms of asthma. It is
'/>"/>

SOURCE MedImmune, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
11. Malvern initiates European user group meetings for chemical imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited (ASX:BNO, ... development of innovative therapeutics for the treatment of diseases ... announced that its BNC101 IND submission has passed review ... plans to initiate a Phase 1 clinical trial in ... metastatic pancreatic cancer prior to 31 December 2015. ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/wmn42n/prescription_pain ) has ... Drugs - Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ ... Opportunities: 2015 - 2020 Analysis and Forecasts" ... is defined as an unpleasant sensory and emotional ... At some point, everyone experiences pain. Pain may ...
Breaking Medicine Technology:Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... announced that the U.S. Food and Drug Administration ... treatment of adult patients with glioblastoma multiforme (GBM) ...  The portable, wearable device delivers an anti-mitotic, anti-cancer ... The NovoTTF is a novel, first-in-class treatment option ...
... 2011 StelKast is proud to announce the ... Acetabular Liners. EXp™, a blend of antioxidant and ... consulting support of Steven Kurtz, Ph.D. and Exponent, ... clearance for large diameter cobalt-chrome femoral heads and ...
Cached Medicine Technology:FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 2FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 3FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 4A Better Acetabular Solution from StelKast ... Naturally 2
(Date:8/31/2015)... ... August 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film ... a Lookup Table that contains a mathematical formula for modifying an image. The LUT changes ... 60 soft CUBE LUT files. , FCPX LUT Soft requires Final Cut Pro X ...
(Date:8/31/2015)... ... 31, 2015 , ... How can healthcare meet the challenge ... , In a commentary for The American Journal of Managed Care , ... efficacy,” which would bind parties together in agreements to intervene at the earliest ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... print and digital marketing communications company announced today that it has officially launched ... DP President, the new website and brand refresh are more closely aligned with ...
(Date:8/31/2015)... ... , ... The dental implant and prosthetic market in the U.S. is projected ... Press Room ) More than 30 million Americans are missing all their teeth ... for dental implants, the National Association of Dental Laboratories (NADL) created the “What’s In ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... franchise business with a ribbon-cutting ceremony on Aug. 26, generously hosted by the ... booking inspection appointments via AdvantaClean’s National Call Center and website since Aug. 17. ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2
... been stepped up in China, the official Xinhua news agency ... much dreaded Avian influenza or “bird flu” caused by H5N1 ... ago. China has accelerated efforts to monitor bird flu status ... at large and officials have been urged to keep an ...
... evidence supporting the view that ancient men did perform brain ... claim to have unearthed a skull which appears to date ... The skull was found during excavations that were being carried ... ,Georgi Nehrizov informed the press that the skull, which they ...
... the total spending on Medicaid has shown its slowest pace ... a better economy// that has held down new enrollments, cost-containment ... according to a new survey. ,Medicaid is the state-federal health ... of 2.8 percent in fiscal 2006, according to the survey ...
... authority in organ transplantation and an eminent personality delivered ... (CMCH) Ludhiana recently. ,Speaking at the gathering he ... information about organ donation in India and how exactly ... organs after death. ,He observed that for ...
... States will be oganised by the Union Health and Family ... agenda is to come out with a plan to combat ... in India. Chikungunya has taken several lives, predominantly in Kerala. ... of the Health Ministers of the four southern States, Gujarat, ...
... by her ovaries according to a new report.The study conducted ... women put more time and effort into their appearance when ... and makeup affected at that time of the month a ... other alter as well. ,Study's lead author, UCLA ...
Cached Medicine News:Health News:Lowest Spending growth in US Medicaid 2Health News:Crying Need for Awareness on Organ Donation in India: Sir Peter Morris 2Health News:Women’s Fashion Sense Linked to Her Ovulatio 2
9mm Curved Blades with Sharp Pointed Tips; overall length 90mm; Stainless Steel....
Straight shaft with fine pointed 0.3mm Tips for Grasping Delicate Capsule; In Titanium....
Smooth colibri tip; In Titanium....
45 Degree Angle With 0.3, 12 Teeth with 5mm Tying Platform; In Titanium....
Medicine Products: